import { deepFreeze } from "../utils";

export type ClinrtWorldBlogSection = Readonly<{
  title: string;
  paragraphs?: readonly string[];
  bullets?: readonly string[];
}>;

export type ClinrtWorldBlogArticle = Readonly<{
  eyebrow: string;
  title: string;
  summary: string;
  meta: string;
  readTime: string;
  featured?: boolean;
  lead: readonly string[];
  sections: readonly ClinrtWorldBlogSection[];
  closing: readonly string[];
}>;

const blogArticles = [
  {
    eyebrow: "Change Management",
    title: "Managing Mid-Study Changes in IRT in Clinical Trials",
    summary:
      "How protocol amendments, supply updates, and live study changes can be managed in IRT without disrupting timelines, data integrity, or site execution.",
    meta: "Clinical operations blog",
    readTime: "7 min read",
    featured: true,
    lead: [
      "In clinical trials, change is not an exception - it is an expectation. Protocol amendments are often introduced mid-study to address safety findings, regulatory feedback, or evolving scientific requirements. When those changes affect the IRT system, their impact can be significant.",
      "Mid-study changes that involve IRT can directly influence trial timelines, data integrity, and drug supply continuity. Because IRT supports both randomization and drug supply management, updates introduced after go-live carry an operational risk that demands structured planning and careful execution.",
    ],
    sections: [
      {
        title: "Understanding Mid-Study Changes from an IRT Perspective",
        paragraphs: [
          "Mid-study changes refer to any trial modifications implemented after patient enrollment has begun and the IRT system is already in active use.",
        ],
        bullets: [
          "Adjustments to randomization schemas or ratios",
          "Addition or removal of treatment arms",
          "Introduction of new sites or countries",
          "Updates to stratification factors",
          "Modifications to visit schedules that impact drug dispensing",
          "Changes to drug supply, resupply, or packaging strategies",
        ],
      },
      {
        title: "Why Mid-Study IRT Changes Create Operational Risk",
        paragraphs: [
          "Once an IRT system is live, patients are already assigned to treatment arms, drug inventory has moved into the field, sites are enrolling and dispensing per existing rules, and regulatory expectations for traceability remain unchanged.",
          "A change in randomization ratio, for example, can create immediate supply imbalance if the updated strategy is not aligned with inventory already in circulation. High-enrolling sites may experience shortages while slow-enrolling sites retain excess stock.",
        ],
      },
      {
        title: "Common IRT Challenges During Mid-Study Amendments",
        paragraphs: [
          "Many issues associated with mid-study changes do not come from system limitations alone. They are often driven by process gaps, timing pressure, and cross-functional misalignment.",
        ],
        bullets: [
          "Protocol amendments planned without early assessment of IRT impact",
          "Limited involvement of supply and IRT teams during change planning",
          "Original IRT designs that are overly complex and hard to adapt",
          "Compressed timelines leading to insufficient testing",
          "Inconsistent communication to sites regarding operational changes",
        ],
      },
      {
        title: "Key Risk Areas That Require Careful Control",
        bullets: [
          "Randomization continuity - ensuring balance is maintained across existing and future patients",
          "Drug supply alignment - synchronizing supply changes with updated randomization logic",
          "Blinding integrity - preventing access issues or inadvertent unblinding",
          "Data consistency - preserving accuracy and traceability across historical and new records",
          "Site operations - avoiding workflow confusion during rollout",
        ],
      },
      {
        title: "Best Practices for Managing Mid-Study IRT Changes",
        paragraphs: [
          "Strong change management starts with discipline and governance. Successful teams treat an IRT amendment as a connected operational update, not a single technical task.",
        ],
        bullets: [
          "Conduct a structured impact assessment across randomization, supply, sites, data, and reporting",
          "Use a controlled deployment strategy to minimize disruption to active enrollment",
          "Align clinical operations, supply, quality, and IRT specialists early",
          "Validate all changes thoroughly in UAT before production release",
          "Maintain documentation and traceability for inspection readiness",
        ],
      },
      {
        title: "Checklist for Implementation",
        bullets: [
          "Conduct a full IRT impact assessment",
          "Validate changes in a test or UAT environment",
          "Align randomization updates with the drug supply strategy",
          "Communicate changes clearly to sites and stakeholders",
          "Maintain complete audit and configuration documentation",
        ],
      },
      {
        title: "Designing IRT Systems with Change in Mind",
        paragraphs: [
          "Mid-study changes are easier to manage when flexibility is considered during initial study design. Simpler, well-structured IRT configurations are typically more resilient to amendments and easier to validate when changes occur.",
        ],
      },
    ],
    closing: [
      "Managing mid-study changes in clinical trials requires more than technical updates. It demands planning, coordination, and disciplined execution across the teams that own randomization, supply, and delivery.",
      "When approached with structured impact assessment, controlled deployment, and clear communication, IRT changes can be implemented without compromising trial timelines, data integrity, or supply continuity.",
    ],
  },
  {
    eyebrow: "Supply Forecasting",
    title: "How IRT in Clinical Trials Reduces Drug Wastage and Improves Supply Forecasting",
    summary:
      "A closer look at how IRT connects enrollment, treatment assignment, and inventory visibility to reduce waste and improve supply decisions across active studies.",
    meta: "Drug supply management",
    readTime: "6 min read",
    lead: [
      "Managing investigational drug supply is one of the most complex operational responsibilities in modern research. Supply planning must adapt continuously to changing enrollment patterns, protocol amendments, and site performance.",
      "An effective IRT system helps sponsors and CROs improve supply forecasting by connecting patient randomization with live supply data. Instead of relying only on assumptions made at study startup, teams can respond to actual study activity as it unfolds.",
    ],
    sections: [
      {
        title: "How IRT Reduces Drug Wastage",
        paragraphs: [
          "IRT reduces drug wastage by linking patient enrollment, treatment assignment, and site-level inventory into a single operational framework. This allows teams to align demand with supply, respond to enrollment variability, and avoid over-distribution of investigational product.",
        ],
      },
      {
        title: "Why Drug Wastage Remains a Challenge",
        bullets: [
          "Overestimation of site enrollment potential",
          "Conservative buffer strategies that are never recalibrated",
          "Limited visibility into actual drug consumption",
          "Late-stage protocol changes that leave inventory unused",
          "Inflexible resupply rules across regions",
        ],
      },
      {
        title: "The Role of IRT in Supply and Forecasting",
        paragraphs: [
          "The role of IRT extends beyond randomization. It acts as the central operational layer that records patient randomization, visit confirmation, and drug dispensation.",
        ],
        bullets: [
          "Monitor site-level inventory against actual enrollment",
          "Identify emerging demand patterns",
          "Adjust resupply parameters with greater confidence",
          "Maintain oversight across depots, regions, and sites",
        ],
      },
      {
        title: "How Poor Forecasting Leads to Wastage",
        paragraphs: [
          "Supply forecasting often starts with enrollment assumptions that rarely remain accurate throughout a study. When forecasts are not revised, imbalances follow.",
          "If a study modifies its randomization ratio mid-study and the update is not aligned with the supply strategy, high-enrolling sites may experience shortages while slow-enrolling sites retain excess stock. Over time, this increases wastage and drives avoidable logistics effort.",
        ],
      },
      {
        title: "How IRT Improves Forecasting Accuracy",
        bullets: [
          "Continuous forecast recalibration based on enrollment and dispensing behavior",
          "Predictive adjustment of supply thresholds as site performance evolves",
          "Evaluation of scenario impacts when new sites are added or protocols change",
          "Stronger demand alignment that reduces dependence on excess buffer stock",
        ],
      },
      {
        title: "Balancing Availability and Efficiency",
        paragraphs: [
          "One of the primary goals of IRT drug supply management is balancing patient access with operational efficiency across the clinical trial supply chain.",
        ],
        bullets: [
          "Enable smaller, more controlled shipment strategies",
          "Reveal redistribution opportunities earlier",
          "Reduce emergency shipments caused by limited visibility",
          "Support consistent oversight across regions",
        ],
      },
      {
        title: "Best Practices for Reducing Drug Wastage",
        bullets: [
          "Design supply strategies that adapt to enrollment behavior",
          "Align randomization logic with expected consumption patterns",
          "Review supply assumptions regularly throughout the study",
          "Use IRT data as an input for ongoing forecasting decisions",
          "Coordinate closely across clinical, supply, and IRT teams",
        ],
      },
      {
        title: "Designing for Forecasting Resilience",
        paragraphs: [
          "Supply challenges often arise not from poor execution, but from rigid design. Studies benefit most when IRT configurations are built with flexibility in mind.",
        ],
        bullets: [
          "Parameter-driven design that allows thresholds to be adjusted without full reconfiguration",
          "Modular supply logic that supports regional or cohort-specific behavior",
          "Configurable resupply rules that can evolve as enrollment patterns change",
        ],
      },
    ],
    closing: [
      "In modern clinical research, IRT plays a central role in reducing drug wastage and improving supply forecasting across the trial lifecycle.",
      "By linking randomization activity with structured supply oversight, IRT enables informed decisions that support both patient continuity and operational efficiency.",
    ],
  },
  {
    eyebrow: "IRT Design",
    title:
      "Common IRT Design and Configuration Mistakes in Clinical Trials and How to Avoid Them",
    summary:
      "The most common IRT design mistakes do not come from platform limits. They come from early decisions that make systems harder to test, harder to change, and harder for sites to use well.",
    meta: "System design and configuration",
    readTime: "7 min read",
    lead: [
      "Interactive Response Technology systems are fundamental to the execution of modern studies. In clinical trials, they control patient randomization, support drug supply workflows, and help preserve blinding.",
      "Despite their importance, many IRT-related issues arise not from technology limitations, but from early design and configuration decisions. Once a system goes live, correcting foundational gaps becomes difficult and risky.",
    ],
    sections: [
      {
        title: "What Are Common IRT Design Mistakes?",
        paragraphs: [
          "Common IRT design mistakes include over-complex system logic, misalignment with protocol requirements, rigid configuration that limits change, and insufficient testing. These issues often lead to site confusion, operational delays, and increased risk during mid-study updates.",
        ],
      },
      {
        title: "Why Design Decisions Matter",
        paragraphs: [
          "IRT design is sometimes treated as a purely technical step. In reality, every design decision influences how the study operates day to day.",
        ],
        bullets: [
          "Consistent randomization behavior",
          "Predictable drug supply execution",
          "Clear and efficient site workflows",
          "Controlled handling of mid-study changes",
        ],
      },
      {
        title: "Mistake 1: Over-Complicating the IRT System Design",
        paragraphs: [
          "A common error in IRT system design is unnecessary complexity. While protocols can be detailed, the platform does not need to replicate every theoretical scenario.",
        ],
        bullets: [
          "Excessive randomization layers",
          "Conditional workflows that rarely apply",
          "Custom logic that is difficult to test or modify",
        ],
      },
      {
        title: "Mistake 2: Protocol and IRT Configuration Misalignment",
        paragraphs: [
          "Misalignment between the protocol and IRT configuration is a frequent source of confusion. This happens when protocol language is open to interpretation, configuration decisions are made without enough clinical input, or protocol updates are not fully reflected in system logic.",
        ],
      },
      {
        title: "Mistake 3: Designing Without Site Workflow in Mind",
        paragraphs: [
          "IRT systems are used daily by site staff, often under time pressure. Designs that ignore site workflows increase error rates and support burden.",
        ],
        bullets: [
          "Too many steps for simple actions",
          "Unclear terminology or prompts",
          "Limited safeguards against incorrect selections",
        ],
      },
      {
        title: "Mistake 4: Rigid Configuration That Limits Change",
        paragraphs: [
          "Clinical trials evolve, but some IRT systems are designed with little flexibility. Rigid configuration makes mid-study updates difficult and increases validation effort.",
          "Using parameter-driven logic and configurable thresholds makes controlled adjustments possible without redesigning the whole study setup.",
        ],
      },
      {
        title: "Mistake 5: Inadequate Testing of IRT Configuration",
        paragraphs: [
          "Insufficient testing remains one of the most avoidable mistakes in IRT implementation.",
        ],
        bullets: [
          "Limited coverage of country-specific scenarios",
          "Incomplete simulation of enrollment variation",
          "Minimal testing of amendment scenarios",
        ],
      },
      {
        title: "Best Practices for Stronger IRT Design",
        bullets: [
          "Conduct structured design review checkpoints before build begins",
          "Align IRT design with the supply strategy early in planning",
          "Simulate real study scenarios during UAT, not just ideal paths",
          "Design configuration layers that allow controlled change",
          "Clearly document rationale and assumptions",
        ],
      },
      {
        title: "Designing for the Full Clinical Trial Lifecycle",
        paragraphs: [
          "Effective IRT system design must support the full lifecycle of a study, not just startup. Designs that use parameter-based rules, modular supply logic, and configurable resupply thresholds are better equipped to handle amendments, site additions, and shifting enrollment patterns without disruption.",
        ],
      },
    ],
    closing: [
      "Most IRT challenges in clinical trials originate from early design decisions. Choices made during initial configuration define how well the system performs months or even years later.",
      "Strong IRT design is not about complexity, but about foresight and control. When systems are designed with clarity, flexibility, and real-world execution in mind, they support stable and confident trial delivery.",
    ],
  },
] satisfies readonly ClinrtWorldBlogArticle[];

export const clinrtWorldBlogArticles = deepFreeze(blogArticles);
